Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Escudier

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'ImmunothérapieA Ravaud, B Audhuy, F Gomez, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 1, 2012
[Current role of lymph node dissection in renal cell carcinoma: review of the literature by the Oncology Committee of the French Association of Urology (CCAFU)]P Paparel, J-A Long, H Baumert, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 25, 2009
[Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comité de cancérologie de l'Association française d'urologie (CCAFU)]Y Neuzillet, J A Long, P Paparel, et al.
Clinical and Experimental Immunology|December 22, 1999
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patientsN Haicheur, B Escudier, T Dorval, et al.
Clinical Genitourinary Cancer|December 3, 2014
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT studyD Jäger, J H Ma, J Mardiak, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[Do ablative treatments modify the management of kidney tumors in the elderly?]J-A Long, Y Neuzillet, L Poissonnier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[The place of laparoscopic nephrectomy in the elderly subject]P Paparel, J-A Long, Y Neuzillet, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2010
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinibB Beuselinck, S Oudard, O Rixe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†A Ravaud, S Oudard, M De Fromont, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'ImmunothérapieA Ravaud, B Audhuy, F Gomez, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|May 1, 2012
[Current role of lymph node dissection in renal cell carcinoma: review of the literature by the Oncology Committee of the French Association of Urology (CCAFU)]P Paparel, J-A Long, H Baumert, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|August 25, 2009
[Clamping modalities during partial nephrectomy: technical aspects and functional consequences. Review by the Comité de cancérologie de l'Association française d'urologie (CCAFU)]Y Neuzillet, J A Long, P Paparel, et al.
Clinical and Experimental Immunology|December 22, 1999
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patientsN Haicheur, B Escudier, T Dorval, et al.
Clinical Genitourinary Cancer|December 3, 2014
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT studyD Jäger, J H Ma, J Mardiak, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[Do ablative treatments modify the management of kidney tumors in the elderly?]J-A Long, Y Neuzillet, L Poissonnier, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 4, 2010
[The place of laparoscopic nephrectomy in the elderly subject]P Paparel, J-A Long, Y Neuzillet, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2010
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinibB Beuselinck, S Oudard, O Rixe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†A Ravaud, S Oudard, M De Fromont, et al.
Pageof 19